-
ASCO 2025 Expert Dialogue | Dr. Changsong Qi & Dr. Kohei Shitara: Breakthroughs with T-DXd and CAR-T Therapy Reshape the Outlook for Advanced Gastric
Two pivotal studies in targeted therapy for gastric cancer drew significant attention at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The world’s first randomized controlled trial (RCT) of CAR-T therapy in solid tumors (Abstract #4003) produced positive results, demonstrating the superior efficacy and manageable safety profile of Claudin 18.2-targeted CAR-T compared to…
-
ASCO 2025 | Dr. Wentao Fang on CheckMate 577: Adjuvant Immunotherapy Significantly Improves Survival in Non-pCR Esophageal Cancer Patients After nCRT
At the 2025 ASCO Annual Meeting, updated survival data from the CheckMate 577 trial reignited discussion within the global oncology community. The study focused on patients with esophageal or gastroesophageal junction (GEJ) cancer who had received neoadjuvant chemoradiotherapy (nCRT) followed by surgery but did not achieve a pathologic complete response (non-pCR). In this high-risk subgroup,…
-
2025 Peking University Urology Academic Forum | Prof. Tianxin Lin (Sun Yat-sen Memorial Hospital of Sun Yat-sen University)
Prof. Tianxin Lin delivered an insightful presentation on the application of artificial intelligence in the precision diagnosis and treatment of bladder cancer. He highlighted the current diagnostic challenges related to…
Connecting Medical Expertise through Media
